Details of the Drug

General Information of Drug (ID: DM3OBQF)

Drug Name

Belimumab

Synonyms

Belimumab (USAN); LymphoStat-B; LymphoStat-B (TN)

Indication

Disease Entry	ICD 11	Status	REF
Systemic lupus erythematosus	4A40.0	Approved	[1], [2]

Drug Type

Antibody

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 19.4 days [3]
Metabolism: The drug is metabolized via proteolytic enzymes [4]

Cross-matching ID

DrugBank ID: DB08879
TTD ID: D05IQX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell-activating factor (TNFSF13B)	TTWMIDN	TN13B_HUMAN	Not Available	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Belimumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Belimumab and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[13]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Belimumab and Tecfidera.	Multiple sclerosis [8A40]	[14]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Belimumab and Siponimod.	Multiple sclerosis [8A40]	[15]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Belimumab and Ocrelizumab.	Multiple sclerosis [8A40]	[16]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Belimumab and Ozanimod.	Multiple sclerosis [8A40]	[17]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Belimumab when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[18]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6887).
2	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013 Sep 1;72(9):1461-8.
8	Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914.
9	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
10	Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo. PLoS One. 2012; 7(10): e47361.
11	BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets. 2003 Feb;7(1):115-23.
12	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
13	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
14	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
15	Cerner Multum, Inc. "Australian Product Information.".
16	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]